SG11202111131VA - Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations - Google Patents
Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrationsInfo
- Publication number
- SG11202111131VA SG11202111131VA SG11202111131VA SG11202111131VA SG11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA SG 11202111131V A SG11202111131V A SG 11202111131VA
- Authority
- SG
- Singapore
- Prior art keywords
- amorphous solid
- plasma concentrations
- enhanced performance
- therapeutic plasma
- achieving therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832606P | 2019-04-11 | 2019-04-11 | |
| PCT/US2020/027677 WO2020210629A1 (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111131VA true SG11202111131VA (en) | 2021-11-29 |
Family
ID=70465560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111131VA SG11202111131VA (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12509461B2 (https=) |
| EP (1) | EP3953355A1 (https=) |
| JP (2) | JP2022526656A (https=) |
| KR (1) | KR20210151183A (https=) |
| CN (1) | CN113924300A (https=) |
| AR (1) | AR118650A1 (https=) |
| AU (2) | AU2020271103B2 (https=) |
| BR (1) | BR112021020257A2 (https=) |
| CA (1) | CA3132530A1 (https=) |
| CL (1) | CL2021002627A1 (https=) |
| CO (1) | CO2021015054A2 (https=) |
| EA (1) | EA202192753A1 (https=) |
| IL (1) | IL287103A (https=) |
| MX (2) | MX2021012288A (https=) |
| PE (1) | PE20212367A1 (https=) |
| SG (1) | SG11202111131VA (https=) |
| TW (1) | TW202104228A (https=) |
| WO (1) | WO2020210629A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023010629A (es) | 2021-03-09 | 2023-09-19 | Bayer Ag | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida. |
| TW202327607A (zh) | 2021-09-17 | 2023-07-16 | 美商必治妥美雅史谷比公司 | 用於預防及治療血管栓塞病症之米爾維仙(milvexian) |
| UY40381A (es) | 2022-08-01 | 2024-01-31 | Janssen Pharmaceutica Nv | Uso de milvexian para el tratamiento o la prevención del accidente cerebrovascular isquémico |
| CN120712076A (zh) | 2023-02-06 | 2025-09-26 | 百时美施贵宝公司 | 米尔维仙药物组合物 |
| WO2025099743A1 (en) * | 2023-11-07 | 2025-05-15 | Dr. Reddy’S Laboratories Limited | Process for preparation of milvexian and solid-state forms thereof |
| WO2025126240A1 (en) * | 2023-12-12 | 2025-06-19 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions and use thereof |
| WO2025220042A1 (en) * | 2024-04-18 | 2025-10-23 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising asundexian and use thereof |
| WO2025224678A1 (en) | 2024-04-25 | 2025-10-30 | Assia Chemical Industries Ltd. | Solid state forms of milvexian and process for preparation thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK569786A (da) | 1985-11-27 | 1987-05-28 | Syntex Inc | Benzimidazolderivater |
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| GEP20053427B (en) * | 1999-12-23 | 2005-01-25 | Pfizer Prod Inc | Pharmaceutical Compositions Providing Enhanced Drug Concentrations |
| ES2598178T5 (es) * | 2008-10-07 | 2023-12-26 | Kudos Pharm Ltd | Formulación farmacéutica 514 |
| WO2010102245A1 (en) | 2009-03-05 | 2010-09-10 | Upsher-Smith Laboratories, Inc. | Solid dispersion comprising resveratrol |
| KR101739994B1 (ko) * | 2009-04-03 | 2017-05-25 | 에프. 호프만-라 로슈 아게 | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 |
| CN116987080A (zh) * | 2014-01-31 | 2023-11-03 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
| PT107568B (pt) | 2014-03-31 | 2018-11-05 | Hovione Farm S A | Processo de secagem por atomização para a produção de pós com propriedades melhoradas. |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (https=) * | 2014-10-01 | 2018-10-20 | ||
| JP6203702B2 (ja) | 2014-11-18 | 2017-09-27 | 信越化学工業株式会社 | ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法 |
| PT3445767T (pt) | 2016-04-22 | 2020-05-13 | Astrazeneca Ab | Inibidores de mcl-1 macrocíclicos para o tratamento de cancro |
-
2020
- 2020-04-10 TW TW109112257A patent/TW202104228A/zh unknown
- 2020-04-10 MX MX2021012288A patent/MX2021012288A/es unknown
- 2020-04-10 EA EA202192753A patent/EA202192753A1/ru unknown
- 2020-04-10 BR BR112021020257A patent/BR112021020257A2/pt unknown
- 2020-04-10 JP JP2021559853A patent/JP2022526656A/ja not_active Withdrawn
- 2020-04-10 PE PE2021001691A patent/PE20212367A1/es unknown
- 2020-04-10 CA CA3132530A patent/CA3132530A1/en active Pending
- 2020-04-10 CN CN202080041944.7A patent/CN113924300A/zh active Pending
- 2020-04-10 US US17/602,025 patent/US12509461B2/en active Active
- 2020-04-10 WO PCT/US2020/027677 patent/WO2020210629A1/en not_active Ceased
- 2020-04-10 SG SG11202111131VA patent/SG11202111131VA/en unknown
- 2020-04-10 AU AU2020271103A patent/AU2020271103B2/en active Active
- 2020-04-10 KR KR1020217036797A patent/KR20210151183A/ko not_active Ceased
- 2020-04-10 EP EP20722195.3A patent/EP3953355A1/en active Pending
- 2020-04-13 AR ARP200101025A patent/AR118650A1/es unknown
-
2021
- 2021-10-07 CL CL2021002627A patent/CL2021002627A1/es unknown
- 2021-10-07 IL IL287103A patent/IL287103A/en unknown
- 2021-10-07 MX MX2025011559A patent/MX2025011559A/es unknown
- 2021-11-08 CO CONC2021/0015054A patent/CO2021015054A2/es unknown
-
2025
- 2025-05-20 JP JP2025083936A patent/JP2025131625A/ja active Pending
- 2025-07-25 US US19/281,444 patent/US20260042761A1/en active Pending
- 2025-12-11 AU AU2025279715A patent/AU2025279715A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020271103A1 (en) | 2021-12-02 |
| IL287103A (en) | 2021-12-01 |
| US20220144835A1 (en) | 2022-05-12 |
| US20260042761A1 (en) | 2026-02-12 |
| AU2020271103B2 (en) | 2026-01-08 |
| WO2020210629A1 (en) | 2020-10-15 |
| AU2025279715A1 (en) | 2026-01-15 |
| AR118650A1 (es) | 2021-10-20 |
| PE20212367A1 (es) | 2021-12-21 |
| TW202104228A (zh) | 2021-02-01 |
| MX2025011559A (es) | 2025-11-03 |
| JP2022526656A (ja) | 2022-05-25 |
| US12509461B2 (en) | 2025-12-30 |
| JP2025131625A (ja) | 2025-09-09 |
| EP3953355A1 (en) | 2022-02-16 |
| EA202192753A1 (ru) | 2022-01-11 |
| CO2021015054A2 (es) | 2021-11-19 |
| MX2021012288A (es) | 2021-11-12 |
| CA3132530A1 (en) | 2020-10-15 |
| CL2021002627A1 (es) | 2022-05-06 |
| BR112021020257A2 (pt) | 2021-12-07 |
| KR20210151183A (ko) | 2021-12-13 |
| CN113924300A (zh) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287103A (en) | Improved performance of amorphous solids and factor formulations to achieve therapeutic plasma concentrations | |
| EP4149460B8 (en) | Therapeutic solid dosage forms | |
| GB2587486B (en) | Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof | |
| EP4058190A4 (en) | COMPOSITIONS AND METHODS FOR THE CONTROLLED DELIVERY AND PROTECTION OF THERAPEUTICS | |
| PH12013501574A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| PH12013501591A1 (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| IN2013MU01696A (https=) | ||
| IL287260A (en) | Preparations and methods for the treatment of cystic fibrosis | |
| EP4284272A4 (en) | COMPOSITIONS AND METHODS OF SUSTAINED TREATMENT OF PAIN | |
| IL291543A (en) | Medical preparations and their use | |
| IL277913A (en) | Preparations containing strontium and methylsulfonylmethane (MSM) and their uses in treatment methods | |
| IL289236A (en) | Preparations and methods for treating fungal infections | |
| EP4138852A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PAIN | |
| EP4164619A4 (en) | TREATMENT METHODS AND FORMULATIONS | |
| HK40068978A (en) | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations | |
| EP4017873A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | |
| EP4072549A4 (en) | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DIASTOLIC DYSFUNCTION | |
| EP3976115A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HEMOCHROMATOSIS | |
| GB202101161D0 (en) | Formulations for the treatment of tendinopathies | |
| HK40089059A (en) | Compositions and methods for the treatment of tdp-43 proteinopathies | |
| GB202001137D0 (en) | Formulations for the treatment of tendinopathies | |
| HK40065186A (en) | Therapeutic agents and methods of treatment | |
| HK40102245A (en) | Dsg2 compositions and methods for the treatment of covid-19 | |
| HK40115420A (en) | Treatment of nociceptive pain | |
| HK40064531B (en) | Therapeutic solid dosage forms |